This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

44/100

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Brain scans and imaging

Topic: Brain proteins, microglia and lab models

In vitro binding assays demonstrated a high binding affinity of 18 F-SMBT-1 to MAO-B (dissociation constant, 3.7 nM). In contrast, it showed low binding affinity to MAO-A and protein aggregates such as amyloid-β and tau fibrils. Autoradiographic analysis showed higher amounts of 18 F-SMBT-1 binding in the Alzheimer disease brain sections than in the control brain sections. 18 F-SMBT-1 binding was completely displaced with the reversible MAO-B inhibitor lazabemide, demonstrating the high selectivity of 18 F-SMBT-1 for MAO-B. Furthermore, 18 F-SMBT-1 showed a high uptake by brain, rapid washout, and no radiolabeled metabolites in the brain of normal mice. 18 F-SMBT-1 showed no significant binding to various receptors, ion channels, or transporters, and no toxic effects related to its administration were observed in mice and rats. 18 F-SMBT-1 is a promising and selective MAO-B PET tracer candidate, which would be useful for quantitative monitoring of astrogliosis in the human brain.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Harada, R., Hayakawa, Y., Ezura, M., Lerdsirisuk, P., Du, Y., Ishikawa, Y., et al. (2021). 18F-SMBT-1: A Selective and Reversible PET Tracer for Monoamine Oxidase-B Imaging. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. https://doi.org/10.2967/jnumed.120.244400

Vancouver

Harada R, Hayakawa Y, Ezura M, Lerdsirisuk P, Du Y, Ishikawa Y, et al. 18F-SMBT-1: A Selective and Reversible PET Tracer for Monoamine Oxidase-B Imaging. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2021. doi:10.2967/jnumed.120.244400. PMID: 32646880.

BibTeX

@article{harada2021-32646880,
  author  = {Harada, R. and Hayakawa, Y. and Ezura, M. and Lerdsirisuk, P. and Du, Y. and Ishikawa, Y. and Iwata, R. and Shidahara, M. and others},
  title   = {{18F-SMBT-1: A Selective and Reversible PET Tracer for Monoamine Oxidase-B Imaging}},
  journal = {Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year    = {2021},
  doi     = {10.2967/jnumed.120.244400},
  pmid    = {32646880},
  url     = {https://doi.org/10.2967/jnumed.120.244400}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

In vitro binding assays demonstrated a high binding affinity of 18 F-SMBT-1 to MAO-B (dissociation constant, 3.7 nM).
In contrast, it showed low binding affinity to MAO-A and protein aggregates such as amyloid-β and tau fibrils.
Autoradiographic analysis showed higher amounts of 18 F-SMBT-1 binding in the Alzheimer disease brain sections than in the control brain sections. 18 F-SMBT-1 binding was completely displaced with the reversible MAO-B inhibitor lazabemide, demonstrating the high selectivity of 18 F-SMBT-1 for MAO-B.
Furthermore, 18 F-SMBT-1 showed a high uptake by brain, rapid washout, and no radiolabeled metabolites in the brain of normal mice. 18 F-SMBT-1 showed no significant binding to various receptors, ion channels, or transporters, and no toxic effects related to its administration were observed in mice and rats.

Why it matters

This laboratory study describes a new PET tracer, 18F-SMBT-1, that binds selectively to MAO-B and may be useful for monitoring astrogliosis in the brain. It is early, mainly in-vitro and animal work, and does not test any treatment, cure or prevention for Alzheimer's disease.

New to this subject? Start with our plain-English guide: Brain scans & tests →

Study details

Evidence strengthLow

How this study scored 44/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Journal of nuclear medicine : official publication, Society of Nuclear Medicine)
Journal's citation record	2 / 4	Journal of Nuclear Medicine: journal h-index 230 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	3 / 5	2021 — within 6 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	4 / 7	Cited 89 times (OpenAlex, 2026-10-10)
Citations per year	3 / 5	12.7 citations a year over 7 year(s) since 2021
Impact for its field and year	3 / 6	Cited 6.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	2 / 6	Cited by 3 other studies in this library
Still being cited	2 / 4	Cited 33 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Nobuyuki Okamura: h-index 64 (OpenAlex, whole career)
Institution's track record	1 / 3	Tohoku University: institution h-index 880 (OpenAlex)
Multicenter collaboration	1 / 3	OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 32646880)
Free to read	0 / 2	Behind a paywall — scores zero
Total	44 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

3 studies in the alzhub library list this one in their references.

Related studies in Brain scans and imaging

Also tagged “machine”

834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Brain scans and imaging

See all studies in Brain scans and imaging →